Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 immune alloreactivity study after kidney transplantation
NL-OMON42873Active, not recruiting
- Sponsor
- Nierziekten
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Single-arm trial of iscalimab in kidney transplant, sponsored by Nierziekten. Primary endpoints: Peripheral blood immune cell number and phenotype, Tfh-memory B-cell interaction under co-stimulation blockade and 5 more. Started Aug 2016; status: active, not recruiting.
02
Drugs
iscalimab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON42873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42873.